What is Adela?
Adela Bio is a biotechnology firm at the forefront of developing advanced blood-based solutions for cancer detection and monitoring. Leveraging sophisticated DNA methylation-based liquid biopsy technology, the company aims to enhance early cancer identification, provide precise assessment of treatment efficacy, and track disease recurrence. This focus on less invasive and more accurate cancer care positions Adela Bio as a key player in the evolving landscape of precision oncology.
How much funding has Adela raised?
Adela has raised a total of $53M across 2 funding rounds:
Other Financing Round
$48M
Debt
$5M
Other Financing Round (2023): $48M with participation from F-Prime Capital Partners, Deerfield, Decheng Capital, RA Capital Management, and OrbiMed
Debt (2026): $5M, investors not publicly disclosed
Key Investors in Adela
F-Prime Capital Partners
F-Prime Capital Partners is an investment firm established in 2002, dedicated to investing in healthcare and technology companies. Based in Massachusetts, they bring a team of investors, engineers, doctors, and scientists to support their portfolio.
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. They support companies across the healthcare ecosystem with flexible funding models and drive innovation using AI, data, and market research.
Decheng Capital
Decheng Capital is a global investment firm founded in 2012, specializing in providing capital and strategic support to early-stage life science and growth-stage healthcare companies. They aim to build leading companies by leveraging revolutionary technologies.
What's next for Adela?
With this substantial backing, Adela Bio is poised to accelerate its research and development initiatives, potentially expanding its clinical trials and further refining its proprietary liquid biopsy platform. The strategic investment suggests a focus on scaling operations and commercializing its solutions, aiming to make a significant impact on patient outcomes through earlier and more effective cancer management. Future growth will likely involve navigating regulatory pathways and establishing key partnerships within the healthcare ecosystem.
See full Adela company page
